Merck Inks New Non-Exclusive Agreement With Roche
Merck & Co said it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of Victrelis as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.
As per the terms of the agreement, Roche and Merck will work together in global markets, including Europe, Asia and Latin America, to educate physicians and patients about hepatitis C virus. The companies previously announced an agreement to promote Victrelis in the United States and collaborate to explore new treatment regimens for patients with chronic HCV.
